Keywords
Phaseolus vulgaris
hypoglycemic activity
diabetes mellitus
Abstract
The aim of the present study was to evaluate the hypoglycemic activity of the aqueous extract from the fruit walls of Phaseolus vulgaris pods and to examine the potential mechanism underlying the improvement of the glycemic level. In the course of the study, diabetes mellitus was induced in rats with a single intraperitoneal injection of streptozotocin (45 mg·kg-1 b.w.). Diabetic and control rats were then orally administered with a single-dose or repeated-dose (28 day) of P. vulgaris extract (200 mg·kg-1). Results show that the extract was found to possess significant hypoglycemic activity, and the study of glucose utilization by isolated rat hemidiaphragm suggests that the aqueous extract may enhance the peripheral utilization of glucose. The subsequent experiments have revealed that the P. vulgaris extract could increase glucose transporter 4 (GLUT-4) content in skeletal muscle cells of control and diabetic rats. Our data also indicate that the P. vulgaris extract did not affect the content of the insulin receptor, but significantly reduced the total tyrosine kinase activity in skeletal muscle cells of both experimental groups of rats. The present results clearly indicated that P. vulgaris extract may be beneficial for reducing hyperglycemia through its potency in regulation of glucose utilization via GLUT-4, but the current mechanism remains to be unidentified.
References
1. IDF Diabetes Atlas 7th Edition 2015.
2. Blair M. Diabetes Mellitus Review. Urol Nurs. 2016;36(1):27-36.
3. Brealey D, Singer M. Hyperglycemia in critical illness: a review. J Diabetes Sci Technol. 2009;3(6):1250-60.
4. Dias DA, Urban S, Roessner U. A Historical Overview of Natural Products in Drug Discovery. Metabolites. 2012;2(2):303-36.
5. Chang CL, Chen YC, Chen HM, et al. Natural cures for type 1 diabetes: a review of phytochemicals, biological actions, and clinical potential. Curr Med Chem. 2013;20(7):899-907.
6. Yeh GY, Eisenberg DM, Kaptchuk TJ, et al. Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care. 2003;26(4):1277-94.
7. Covington MB. Traditional Chinese medicine in the treatment of diabetes. Diabetes Spectr. 2001;14:154-9.
8. Ota A, Ulrih NP. An overview of herbal products and secondary metabolites used for management of type two diabetes. Front Pharmacol. 2017;8:436.
9. Pandey VN, Rajagopalan SS, Chowdhary DP. An effective Ayurvedic hypoglycemic formulation. J Res Ayurveda Siddha. 1995;1-14.
10. Oubre AY, Carlson TJ, King SR, et al. From plant to patient: an ethnomedical approach to the identification of new drugs for the treatment of NIDDM. Diabetologia. 1997;40:614-17.
11. Karimi A, Majlesi M, Rafieian-Kopaei M. Herbal versus synthetic drugs; beliefs and facts. J Nephropharmacol. 2015;4(1):27-30.
12. Bharti SK, Krishnan S, Kumar A, et al. Antidiabetic phyto-constituents and their mode of action on metabolic pathways. Ther Adv Endocrinol Metab. 2018;9(3):81-100.
13. Chávez-Mendoza C, Sánchez E. Bioactive compounds from Mexican varieties of the Common Bean (Phaseolus vulgaris): implications for health. Molecules. 2017;22(8),1360.
14. Reynoso-Camacho R., Ramos-Gomez M., Loarca-Pina G. Bioactive components in common beans (Phaseolus vulgaris L.). Research Signpost. 2006;37/661(2):217-36.
15. Helmstädter A. Beans and diabetes: Phaseolus vulgaris preparations as antihyperglycemic agents. J Med Food. 2010;13(2):251-4.
16. Zafar M, Naqvi S. Effects of STZ-induced diabetes on the relative weights of kidney, liver and pancreas in Albino rats: A comparative study. Int J Morphol. 2010;28(1):135-42.
17. Sabu MC, Subburaju T. Effect of Cassia auriculata Linn. on serum glucose level, glucose utilization by isolated rat hemidiaphragm. J Ethnopharmacol. 2002;80:203-6.
18. Stasevych M, Zvarych V, Lunin V, et al. Novel anthraquinone-based derivatives as potent inhibitors for receptor tyrosine kinases. Indian J Pharm Sci. 2015;77(5):634-7.
19. Carai MAM, Fantini N, Loi B, et al. Potential efficacy of preparations derived from Phaseolus vulgaris in the control of appetite, energy intake, and carbohydrate metabolism. Diabetes Metab Syndr Obes. 2009;2:145-53.
20. Roman-Ramos R, Flores-Saenz JL, Partida-Hernandez G, et al. Experimental study of the hypoglycemic effect of some edible plants. Arch Invest Med (Mex). 1991;22:87-93.
21. Roman-Ramos R, Flores-Saenz JL, Alarcon-Aguilar F. Antihypergly-cemic effect of some edible plants. J Ethnopharmacol. 1995;48:25-32.
22. Pari L, Venkateswaran S. Effect of an aqueous extract of Phaseolus vulgaris on plasma insulin and hepatic key enzymes of glucose metabolism in experimental diabetes. Pharmazie. 2003;58:916-9.
23. Almuaigela MF, Seifb MA, Albualia HW, Alharbia O, Alhawasha A. Hypoglycemic and hypolipidemic effects of aqueous extract of Phaseolus vulgaris pods in streptozotocin-diabetic rats. Biomedicine & Pharmacotherapy. 2017; 94:742-6.
24. Pari L, Venkateswaran S. Protective role of Phaseolus vulgaris on changes in the fatty acid composition in experimental diabetes. J Med Food. 2004;7(2):204-9.
25. Neef H, Declercq P, Laekeman G. Hypoglycemic activity of selected European plants. Phytother Res. 1995;9:45-8.
26. Cerovic A, Miletic I, Konic.-Ristic A, et al. The dry plant extract of common bean seed (Phaseoli vulgari pericarpium) does not have an affect on postprandial glycemia in healthy human subject. Bosn J Basic Med Sci. 2006;6(3):28-33.
27. Kyznetsova MY, Lavrovska DO, Zhyvolozhnyi AY, et al. Effect of aqueous extract from Phaseolus vulgaris pods on cytokine profile of streptozotocin-induced diabetic rats. RJPBCS. 2015;6(1):1511-20.
28. Kyznietsova MY, Halenova TI, Savchuk OM, et al. Carbohydrate metabolism in type 1 diabetic rats under the conditions of the kidney bean pods aqueous extract application. Fiziol Zh. 2015;61(6):96-103.
29. Kyznetsova M, Makieieva O, Lavrovska D, et al. Aqueous extract from Phaseolus vulgaris pods on lipid peroxidation and antioxidant enzymes activity in the liver and kidney of diabetic rats. J Appl Pharm Sci. 2015; 5(5):001-6.
30. Oseguera Toledo ME, Gonzalez de Mejia E, Sivaguru M, et al. Common bean (Phaseolus vulgaris L.) protein-derived peptides increased insulin secretion, inhibited lipid accumulation, increased glucose uptake and reduced the phosphatase and tensin homologue activation in vitro. J Funct Foods. 2016; 27:160-77.
31. Lenzen S. The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia. 2008;51(2):216-26.
32. Lim M, Park L, Shin G, Hong H, Kang I, Park Y. Induction of apoptosis of Beta cells of the pancreas by advanced glycation end-products, important mediators of chronic complications of diabetes mellitus. Ann NY Acad Sci. 2008;1150:311-5.
33. Barrett ML, Udani JK. A proprietary alpha-amylase inhibitor from white bean (Phaseolus vulgaris): a review of clinical studies on weight loss and glycemic control. Nutr J. 2011;10:24.
34. Baintner K, Kiss P, Pfüller U, et al. Effect of orally and intra-peritoneally administered plant lectins on food consumption of rats. Acta Physiol Hung. 2003; 90(2):97-107.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
Copyright (c) 2019 Autors